Pulse Biosciences (NASDAQ: PLSE) — Perfil da empresa, notícias e dados financeiros
Pulse Biosciences develops bioelectric medicine therapies using Nano-Pulse Stimulation technology for various medical fields.

Pulse Biosciences
Pulse Biosciences (NASDAQ:PLSE) is a bioelectric medicine company focused on developing therapeutic tissue treatment platforms based on its proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a non-thermal technology that delivers nanosecond duration pulses of electrical energy to cells and tissues, targeting cellular structures while sparing surrounding non-cellular tissue. This innovative approach has the potential to benefit various applications in oncology, dermatology, and other fields by inducing immunogenic cell death. Pulse Biosciences aims to leverage its unique technology to provide improved outcomes for patients suffering from a variety of diseases. Grounded in rigorous scientific research, the company is committed to pioneering advancements in bioelectric medicine, with ongoing projects designed to expand the utility and application of its NPS technology to meet pressing clinical needs.
Resumo
Operações
Produtos e/ou serviços de Pulse Biosciences
- CellFX System, a proprietary platform utilizing Nano-Pulse Stimulation technology for dermatologic procedures to clear benign lesions.
- Research into non-thermal Nano-Pulse Stimulation technology for potential cancer treatments.
- Development of next-generation devices targeting a range of skin conditions using Nano-Pulse Stimulation technology.
- Investigations into applications of Nano-Pulse Stimulation for cardiology, particularly in arrhythmia treatment.
- Partnership programs with dermatology clinics for the adoption and integration of the CellFX System.
- Initiatives in providing educational resources for healthcare providers on the benefits and applications of Nano-Pulse Stimulation technology.
equipe executiva do Pulse Biosciences
- Paul Arthur LaViolettePresident, CEO & Co-Chairman of the Board
- Jon SkinnerChief Financial Officer
- Darrin R. UeckerCTO & Director
- Liane TeplitskyChief Operating Officer
- Steven T. WeberVP of Accounting, Principal Accounting Officer & Global Corporate Controller
- Kenneth B. StrattonGeneral Counsel & Corporate Secretary
- Patty PerlaVice President of Human Resources
- David DanitzSenior Vice President of Engineering
- Gansevoort DunningtonChief Medical Officer
- Niv AdChief Science Officer of Cardiac Surgery
Últimas notícias sobre a Pulse Biosciences
Principais indicadores financeiros
Resultados divulgados pela Pulse Biosciences, em USD.
- Cap. de mercado
- 3,8 bi
- Receita (TTM)
- 1,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 350 mil | -76,9 mi | -72,8 mi | |
| 0 | -56,3 mi | -53,6 mi | |
| -9 mil | -43,6 mi | -42,2 mi | |
| 700 mil | -58,1 mi | -59 mi |